文献速递前列腺增生与排尿功能障碍

度他雄胺改善夜尿症但不改善睡眠:REDUCE临床试验结果

Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial.
PubMed 文献 · J Urol · 2021-02-19

REDUCE试验纳入6914名前列腺癌风险增高的男性,随机接受度他雄胺0.5mg/天或安慰剂治疗4年。度他雄胺在2年(-0.15,95%CI -0.21至-0.09)和4年(-0.24,95%CI -0.31至-0.18) modestly改善夜尿症,但未改善睡眠质量。在伴有下尿路症状、夜尿症或睡眠不佳的亚组中结果一致。

要点

  • 度他雄胺 modestly改善夜尿症,但对睡眠质量无影响。
  • 伴有睡眠不佳的夜尿症患者可能无法从口服BPH治疗中获益。
  • 亚组分析结果与全队列一致。

核心结论

  • 在伴有睡眠不佳且主诉夜尿症的男性中,度他雄胺治疗下尿路症状可 modestly改善夜尿症,但对睡眠无影响。

研究设计与样本

  • REDUCE是一项为期4年的随机、多中心试验,比较度他雄胺0.5 mg/天与安慰剂用于前列腺癌化学预防。
  • 纳入年龄50-75岁、PSA 2.5-10 ng/ml、一次阴性前列腺活检的前列腺癌风险增高男性。
  • 共6914名男性具有完整基线数据,2年和4年随访评估率分别为80%和59%。

主要发现

  • 度他雄胺在2年时改善夜尿症(-0.15,95% CI -0.21至-0.09),4年时改善夜尿症(-0.24,95% CI -0.31至-0.18)。
  • 度他雄胺未改善睡眠。
  • 在伴有下尿路症状、夜尿症、睡眠不佳或其组合的男性中,结果与全队列一致。

临床怎么用

  • 对于伴有睡眠不佳的夜尿症男性,度他雄胺可能 modestly改善夜尿症,但不应期望改善睡眠。
  • 口服BPH治疗可能对伴有睡眠不佳的夜尿症患者获益有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In men, complaints of nocturia causing poor sleep are often attributed to benign prostatic hyperplasia and treated with benign prostatic hyperplasia medications. We assessed whether treating lower urinary tract symptoms with dutasteride altered either nocturia or sleep quality using data from REDUCE. MATERIALS AND METHODS: REDUCE was a 4-year randomized, multicenter trial comparing dutasteride 0.5 mg/day vs placebo for prostate cancer chemoprevention. Study participants were men considered at increased risk for prostate cancer. Eligibility included age 50-75 years, prostate specific antigen 2.5-10 ng/ml, and 1 negative prostate biopsy. At baseline, 2 years and 4 years, men completed the International Prostate Symptom Score and Medical Outcomes Study Sleep Scale, a 6-item scale assessing sleep. To test differences in nocturia and Medical Outcomes Study Sleep Scale over time, we used linear mixed models adjusted for baseline confounders. Subanalyses were conducted in men symptomatic from lower urinary tract symptoms, nocturia, poor sleep, or combinations thereof. RESULTS: Of 6,914 men with complete baseline data, 80% and 59% were assessed at 2 and 4-year followup, respectively. Baseline characteristics were balanced between treatment arms. Dutasteride improved nocturia at 2 (-0.15, 95% CI -0.21, -0.09) and 4 years (-0.24, 95% CI -0.31, -0.18) but did not improve sleep. When limited to men symptomatic from lower urinary tract symptoms, nocturia, poor sleep or combinations thereof, results mirrored findings from the full cohort. CONCLUSIONS: In men with poor sleep who complain of nocturia, treatment of lower urinary tract symptoms with dutasteride modestly improves nocturia but has no effect on sleep. These results suggest men with poor sleep who complain of nocturia may not benefit from oral benign prostatic hyperplasia treatment.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Kuhlmann PK, Fischer SC, Howard LE, et al. Dutasteride Improves Nocturia but Does Not Lead to Better Sleep: Results from the REDUCE Clinical Trial. J Urol. 2021. PMID: 33605791. doi:10.1097/JU.0000000000001640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。